Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Penile Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

No biomarker	Penile Cancer	No biomarker	Penile Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	TIP Sensitive: A2 - Guideline TIP Sensitive : A2	TIP Sensitive: A2 - Guideline TIP Sensitive : A2
MSI-H/dMMR	Penile Cancer	MSI-H/dMMR	Penile Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Penile Cancer	TMB-H	Penile Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Penile Cancer	PD-L1 expression	Penile Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
TMB-H + PD-L1 expression + MSI-L/dMMR	Penile Cancer	TMB-H + PD-L1 expression + MSI-L/dMMR	Penile Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
TMB-H + PD-L1 expression	Penile Cancer	TMB-H + PD-L1 expression	Penile Cancer	toripalimab Sensitive: C4 – Case Studies toripalimab Sensitive : C4	toripalimab Sensitive: C4 – Case Studies toripalimab Sensitive : C4
CDKN2A mutation	Penile Cancer	CDKN2A mutation	Penile Cancer	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
MSI-L/dMMR	Penile Cancer	MSI-L/dMMR	Penile Cancer	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4